Cattley R C, Popp J A
Department of Experimental Pathology and Toxicology, Research Triangle Park, North Carolina 27709.
Cancer Res. 1989 Jun 15;49(12):3246-51.
In order to characterize the promoting activity of the peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (WY-14,463), male F344 rats which received a single 150-mg/kg dose of diethylnitrosamine (DEN) were fed 0.1% WY-14,643 or 0.05% phenobarbital in the diet for 11, 22, or 54 wk. WY-14,643 promoted the development of ATPase-deficient foci but not GGTase-positive or G6Pase-deficient foci, in contrast to phenobarbital which promoted development of foci detected by all three markers. The mode of promotion of ATPase-deficient foci by WY-14,643 was distinctly different from that of phenobarbital. WY-14,643 primarily increased mean volume of foci at 11 and 22 wk, while phenobarbital primarily increased the numerical density of foci at these time points. At 54 wk, the yield of hepatic neoplasms per liver was higher in rats fed WY-14,643 than in rats fed phenobarbital. To evaluate the possibility that the promotional activity of WY-14,643 was more effective at a later stage in hepatocarcinogenesis, rats receiving a dose of DEN and then phenobarbital in the diet for 11 wk were changed to a diet containing WY-14,643 for an additional 11 or 43 wk. However, WY-14,643 feeding from wk 11 to 22 caused a reduction in volume density of ATPase-deficient foci relative to the volume density of foci at 11 wk. In addition, feeding WY-14,643 from wk 11 to 54 caused similar yields of hepatic neoplasms whether or not phenobarbital was fed for the initial 11 wk. WY-14,643 induced hepatic peroxisome proliferation as indicated by palmitoyl CoA oxidase activity regardless of prior treatment with DEN and/or phenobarbital. The yield of neoplasms in rats not receiving DEN was greater in rats fed WY-14,643 for wk 11 to 54 than in rats fed WY-14,643 for wk 1 to 54. In summary, the peroxisome proliferator WY-14,643 was a more efficient promoter of hepatocarcinogenesis in DEN-initiated rats than phenobarbital. The promotional activity of WY-14,643, when evaluated by stereological analysis and by changing promoters, is distinct from that of phenobarbital, perhaps suggesting different cellular and/or molecular mechanisms of promotion. Understanding the role of promotion by WY-14,643 and other peroxisome proliferators may be important in understanding the mechanism of their hepatocarcinogenicity.
为了表征过氧化物酶体增殖剂[4-氯-6-(2,3-二甲苯胺基)-2-嘧啶基硫代]乙酸(WY-14,463)的促进活性,给单次接受150 mg/kg剂量二乙基亚硝胺(DEN)的雄性F344大鼠喂食含0.1% WY-14,643或0.05%苯巴比妥的饲料,持续11、22或54周。与苯巴比妥促进所有三种标记物检测到的病灶发展不同,WY-14,643促进了ATP酶缺乏病灶的发展,但不促进γ-谷氨酰转肽酶阳性或葡萄糖-6-磷酸酶缺乏病灶的发展。WY-14,643对ATP酶缺乏病灶的促进模式与苯巴比妥明显不同。WY-14,643在11周和22周时主要增加病灶的平均体积,而苯巴比妥在这些时间点主要增加病灶的数量密度。在54周时,喂食WY-14,643的大鼠每肝脏的肝肿瘤产量高于喂食苯巴比妥的大鼠。为了评估WY-14,643的促进活性在肝癌发生后期是否更有效,给接受DEN剂量然后在饲料中喂食苯巴比妥11周的大鼠,改为喂食含WY-14,643的饲料,再持续11或43周。然而,从第11周到第22周喂食WY-14,643导致ATP酶缺乏病灶的体积密度相对于11周时病灶的体积密度降低。此外,无论最初11周是否喂食苯巴比妥,从第11周到第54周喂食WY-14,643导致的肝肿瘤产量相似。无论之前是否用DEN和/或苯巴比妥处理,WY-14,643均诱导肝过氧化物酶体增殖,如棕榈酰辅酶A氧化酶活性所示。未接受DEN的大鼠中,第11周到第54周喂食WY-14,643的大鼠的肿瘤产量高于第1周到第54周喂食WY-14,643的大鼠。总之,过氧化物酶体增殖剂WY-14,643在DEN启动的大鼠中比苯巴比妥更有效地促进肝癌发生。通过体视学分析和改变促进剂评估时,WY-14,643的促进活性与苯巴比妥不同,这可能表明其促进作用的细胞和/或分子机制不同。了解WY-14,643和其他过氧化物酶体增殖剂的促进作用在理解其致癌机制方面可能很重要。